About 71,500 women in the United States are diagnosed with a gynecologic cancer every year, according to the Centers for Disease Control. Researchers from University Hospitals Case Medical Center have developed a more effective way to treat gynecologic cancers, shortening radiation treatment time from five weeks to three days. The method is published in the ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Avastin (bevacizumab) in combination with standard chemotherapy (carboplatin and paclitaxel) as a front-line (first-line following surgery) treatment for women with advanced ovarian cancer. Ovarian cancer is the most deadly of the gynaecological cancers, with approximately 220,000 women diagnosed and 140,000 women ...
Targeted drugs, which block or disrupt particular molecules involved in the growth of tumors, have been shown to be effective treatments against many types of cancer. A new phase 3 clinical trial conducted by the Gynecologic Oncology Group (GOG) showed that a targeted therapy called bevacizumab (Avastin) effectively delayed the progression of advanced ovarian cancer. ...
“With this vaccine, we can clearly generate immune responses that lead to clinical responses in some patients,” said lead researcher James Gulley, M.D., Ph.D., director and deputy chief of the clinical trials group at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute. Gulley and colleagues enrolled 26 patients and assigned them ...
Olaparib, a drug that has shown promise in women with an inherited mutation in their BRCA1 or BRCA2 gene (accounting for about 5%-10% of breast and ovarian cancer cases), has, for the first time, been shown to reduce the size of tumours in a much wider group of ovarian cancer patients without these BRCA gene ...